Current and future roles of bevacizumab in the 1 L therapy of NSCLC include combination therapy with erlotinib and bevacizumab in populations with EGFR-mutations [27, 28] as well as combination therapy with atezolizumab and bevacizumab [29]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.